TXG 10x Genomics, Inc.

Nasdaq 10xgenomics.com


$ 12.90 $ -0.25 (-1.9 %)    

Tuesday, 21-Oct-2025 10:46:09 EDT
QQQ $ 610.38 $ -1.26 (-0.21 %)
DIA $ 469.38 $ 2.26 (0.48 %)
SPY $ 671.39 $ -0.10 (-0.01 %)
TLT $ 92.03 $ 0.04 (0.04 %)
GLD $ 376.92 $ -9.72 (-2.51 %)
$ 13.14
$ 13.25
$ 12.88 x 11
$ 12.91 x 258
$ 12.76 - $ 13.35
$ 6.78 - $ 18.21
6,081,985
na
1.64B
$ 2.00
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-12-2025 12-31-2024 10-K
4 10-29-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 04-30-2024 03-31-2024 10-Q
7 02-15-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-16-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-18-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 02-26-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Collaboration enables researchers to begin exploring 10x single cell tools and datasets conversationally, with spatial applicat...

 cathie-wood-warns-wall-street-is-missing-ais-biggest-opportunity-in-healthcare-calling-it-sleeper-investment-poised-for-massive-returns

Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its p...

 my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

 piper-sandler-initiates-coverage-on-10x-genomics-with-neutral-rating-announces-price-target-of-15

Piper Sandler analyst David Westenberg initiates coverage on 10x Genomics (NASDAQ:TXG) with a Neutral rating and announces P...

 10x-genomics-launches-xenium-protein

First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deepe...

 morgan-stanley-maintains-overweight-on-10x-genomics-lowers-price-target-to-17

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $...

 ubs-maintains-neutral-on-10x-genomics-raises-price-target-to-13

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $12 to $13.

 barclays-maintains-overweight-on-10x-genomics-raises-price-target-to-15

Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $13 to ...

 10x-genomics-announces-that-it-has-signed-a-definitive-agreement-to-acquire-scale-biosciences-terms-not-disclosed

 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive ...

 10x-genomics-sees-q3-sales-140000m-144000m-vs-143607m-est

10x Genomics (NASDAQ:TXG) sees Q3 sales of $140.000 million-$144.000 million vs $143.607 million analyst estimate.

 10x-genomics-q2-eps-028-beats-036-estimate-sales-172900m-beat-139408m-estimate

10x Genomics (NASDAQ:TXG) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $(0.36) b...

 b-of-a-securities-maintains-neutral-on-10x-genomics-raises-price-target-to-13

B of A Securities analyst Derik De Bruin maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from...

 barclays-maintains-overweight-on-10x-genomics-raises-price-target-to-13

Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $12 to ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION